Genomics, health care, and society

New England Journal of Medicine

Volumn 365, Issue 11, 2011, Pages 1033-1041

  Hudson, Kathy L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AZATHIOPRINE; CARBAMAZEPINE; CETUXIMAB; CLOPIDOGREL; IRINOTECAN; PANITUMUMAB; PROTRIPTYLINE; TRASTUZUMAB; WARFARIN;

BREAST CANCER; COLORECTAL CANCER; CONFIDENTIALITY; ELECTRONIC MEDICAL RECORD; EPILEPSY; GENETIC ANALYSIS; GENETIC SCREENING; GENOMICS; HEALTH CARE; HUMAN GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; INTEGRATION; LAW ENFORCEMENT; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TRIGEMINUS NEURALGIA; VEIN THROMBOSIS;

EID: 80052859044     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1010517     Document Type: Review

References (73)

1. Feero WG, Guttmacher AE, Collins FS. Genomic medicine - an updated primer. N Engl J Med 2010;362:2001-11.
2. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010;363:166-76.
3. Dietz HC. New therapeutic approaches to mendelian disorders. N Engl J Med 2010;363:852-63.
4. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010;363: 2339-50.
5. GeneTests: Medical Genetics Information Resource (database online). Seattle: University of Washington, 1993-2011. (http://www.genetests.org.)
6. Klein TE, Chang JT, Cho MK, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics J 2001;1:167-70. (Pubitemid 33756654)
7. Skloot R. The immortal life of Henrietta Lacks. New York: Crown, 2010.
8. Lunshof JE, Chadwick R, Vorhaus DB, Church GM. From genetic privacy to open consent. Nat Rev Genet 2008;9:406-11. (Pubitemid 351556065)
9. Valle-Mansilla JI, Ruiz-Canela M, Sulmasy DP. Patients' attitudes to informed consent for genomic research with donated samples. Cancer Invest 2010;28:726-34.
10. Wolf LE, Lo B. Untapped potential: IRB guidance for the ethical research use of stored biological materials. IRB 2004; 26:1-8. (Pubitemid 43362256)
11. Haga SB, Beskow LM. Ethical, legal, and social implications of biobanks for genetics research. Adv Genet 2008;60:505-44.
12. Protection of Human Subjects, 45 C.F.R. § 46 (2005).
13. Office for Human Research Protections. Guidance on research involving coded private information or biological specimens. October 16, 2008. (http://www .hhs.gov/ohrp/policy/cdebiol.html.)
14. Lin Z, Owen AB, Altman RB. Genomic research and human subject privacy. Science 2004;305:183. (Pubitemid 38886715)
15. Homer N, Szelinger S, Redman M, et al. Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet 2008;4(8): e1000167.
16. Kaufman DJ, Murphy-Bollinger J, Scott J, Hudson KL. Public opinion about the importance of privacy in biobank research. Am J Hum Genet 2009;85:643-54.
17. Public Health Service Act, 42 U.S.C. §301(d), 241(d).
18. Cooper ZN, Nelson RM, Ross LF. Certificates of confidentiality in research: rationale and usage. Genet Test 2004;8:214-20. (Pubitemid 39096767)
19. Privacy Certification, 28 C.F.R. §22.23 (1986).
20. Emanuel EJ, Menikoff J. Reforming the regulations governing research with human subjects. N Engl J Med 2011. DOI: 10.1056/NEJMsb1106942.
21. Human subjects research protections: enhancing protections for research subjects and reducing burden, delay, and ambiguity for investigators. Fed Regist 2011; 76(143):44512-31.
22. Greely HT. The uneasy ethical and legal underpinnings of large-scale genomic biobanks. Annu Rev Genomics Hum Genet 2007;8:343-64.
23. Clayton EW, Ross LF. Implications of disclosing individual results of clinical research. JAMA 2006;295:37-8.
24. Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med 2008;5(5):e91.
25. Kaufman D, Murphy J, Scott J, Hudson K. Subjects matter: a survey of public opinions about a large genetic cohort study. Genet Med 2008;10:831-9.
26. Fernandez CV, Gao J, Strahlendorf C, et al. Providing research results to participants: attitudes and needs of adolescents and parents of children with cancer. J Clin Oncol 2009;27:878-83.
27. Clinical Laboratory Improvement Amendments of 1988, Pub. L. No. 100-578.
28. U.S. system of oversight of genetic testing: a response to the charge of the Secretary of Health and Human Services: report of the Secretary's Advisory Committee on Genetics, Health, and Society. Washington, DC: Department of Health and Human Services, April 2008.
29. NIH announces Genetic Testing Registry. News release of the National Institutes of Health, Bethesda, MD, March 18, 2010.
30. FDA to host public meeting on oversight of laboratory-developed tests. News release of the Food and Drug Administration, Silver Spring, MD, June 16, 2010.
31. National Center for Biotechnology Information. Genetic Testing Registry. (http:// www.ncbi.nlm.nih.gov/gtr/.)
32. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4. [Erratum, N Engl J Med 2010;363:1092.]
33. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32.
34. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2. (Pubitemid 34270738)
35. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9. (Pubitemid 351171687)
36. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9. (Pubitemid 46625066)
37. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15. (Pubitemid 351325672)
38. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8. (Pubitemid 46548951)
39. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19.
40. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. (http://www.fda.gov/Drugs/Science Research/ResearchAreas/Pharmaco genetics/ucm083378.htm.)
41. Protriptyline. Florham Park, NJ: Odyssey Pharmaceuticals, 2000 (package insert).
42. Coumadin. New York: Bristol-Myers Squibb, 2010 (package insert).
43. Ziagen. Philadelphia: GlaxoSmithKline, 2010 (package insert).
44. Imuran. San Diego, CA: Prometheus Laboratories, 2008 (package insert).
45. Tegretol. Basel, Switzerland: Novartis, 2009 (package insert).
46. Erbitux. New York: Bristol-Myers Squibb, 2009 (package insert).
47. Plavix. New York: Bristol-Myers Squibb, 2010 (package insert).
48. Camptosar. New York: Pfizer, 2010 (package insert).
49. Vectibix. Thousand Oaks, CA: Amgen, 2009 (package insert).
50. Herceptin. South San Francisco, CA: Genentech, 2010 (package insert).
51. Scheuner MT, de Vries H, Kim B, Meili RC, Olmstead SH, Teleki S. Are electronic health records ready for genomic medicine? Genet Med 2009;11:510-7.
52. McGuire AL, Fisher R, Cusenza P, et al. Confidentiality, privacy, and security of genetic and genomic test information in electronic health records: points to consider. Genet Med 2008;10:495-9.
53. Standards for privacy of individually identifiable health information: final rule. Fed Regist 2000;65(250):82661.
54. Department of Health and Human Services. Understanding HIPPA privacy for covered entities. (http://www.hhs.gov/ ocr/privacy/hipaa/understanding/covered entities/index.html.)
55. Greenbaum D, Du J, Gerstein M. Genomic anonymity: have we already lost it? Am J Bioeth 2008;8:71-4.
56. HIPAA administrative simplification: standards for privacy of individually identifiable health information. Fed Regist 2009;74(193):51698-710.
57. Alonso-Zaldivar R. Senate backs privacy for genetic data: the landmark bill would shield people from insurance and job discrimination based on test results. Los Angeles Times. April 25, 2008.
58. Increased Portability through Limitation on Preexisting Condition Exclusions, 29 U.S.C. § 1181(b)(1)(B)), 18(1)(B)(7)(A).
59. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 2705 (2010).
60. Enforcement and Remedies, 29 C.F.R. § 1635.10 (2009).
61. Baruch S, Hudson K. Civilian and military genetics: nondiscrimination policy in a post-GINA world. Am J Hum Genet 2008;83:435-44.
62. Bonham VL, Dover GJ, Brody LC. Screening student athletes for sickle cell trait - a social and clinical experiment. N Engl J Med 2010;363:997-9.
63. Federal Bureau of Investigation. Combined DNA Index System (CODIS)-NDIS statistics. (http://www.fbi.gov/about-us/ lab/codis/ndis-statistics.)
64. Innocence Project. Facts on post-conviction DNA exonerations. (http://www .innocenceproject.org/Content/Facts-on- PostConviction-DNA-Exonerations.php.)
65. Carlton J. Texan declared innocent after 30 years in prison. New York: Associated Press, January 4, 2011.
66. Duster T. Selective arrests, an ever-expanding DNA forensic database, and the specter of an early-twenty-first-century equivalent of phrenology. In: Lazer D, ed. DNA and the criminal justice system: the technology of justice. Cambridge, MA: MIT Press, 2004:315-34.
67. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
68. Gene patents and licensing practices and their impact on patient access to genetic tests: report of the Secretary's Advisory Committee on Genetics, Health, and Society. April 2010. (http://oba.od.nih.gov/ oba/sacghs/reports/ SACGHS-patents- report-2010.pdf.)
69. Huys I, Berthels N, Matthijs G, Van Overwalle G. Legal uncertainty in the area of genetic diagnostic testing. Nat Biotechnol 2009;27:903-9.
70. Cook-Deegan R, Heaney C. Patents in genomics and human genetics. Annu Rev Genomics Hum Genet 2010;11:383-425.
71. Gold ER, Corbone J. Myriad genetics: in the eye of the policy storm. Genet Med 2010;12:Suppl:S39-S70.
72. The Association for Molecular Pathology v. United States Patent and Trademark Office, No. 09 Civ. 4515 (2009).
73. Department of Justice. Brief for the United States as amicus curiae in support of neither party. The Association for Molecular Pathology v. United States Patent and Trademark Office, No. 2010-1406 (2010).